سوق أنظمة توصيل الجينات - النمو والاتجاهات وتأثير COVID-19 والتوقعات (2023 - 2028)

Table of Contents

1. 1. INTRODUCTION

   1. 1.1 Study Deliverables

   2. 1.2 Study Assumptions

   3. 1.3 Scope of the Study

2. 2. RESEARCH METHODOLOGY

3. 3. EXECUTIVE SUMMARY

4. 4. MARKET DYNAMICS

   1. 4.1 Market Overview

   2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Chronic Diseases and Lifestyle Disorders

      2. 4.2.2 Technological Advancements in Research by Biopharmaceutical Companies

   3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

      2. 4.3.2 Reimbursement Issues

   4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

5. 5. MARKET SEGMENTATION

   1. 5.1 By Delivery Systems

      1. 5.1.1 Viral Gene Delivery Systems

         1. 5.1.1.1 Adenovirus Systems

         2. 5.1.1.2 Lentiviral Systems

         3. 5.1.1.3 Retroviral Systems

         4. 5.1.1.4 Other Viral Gene Delivery Systems

      2. 5.1.2 Non-viral Gene Delivery

      3. 5.1.3 Combined Hybrid Delivery Systems

   2. 5.2 By Application

      1. 5.2.1 Oncology

      2. 5.2.2 Infectious Diseases

      3. 5.2.3 Cardiovascular Disorders

      4. 5.2.4 Diabetes

      5. 5.2.5 Pulmonary Disorders

      6. 5.2.6 Other Applications

   3. 5.3 By Route of Administration

      1. 5.3.1 Oral

      2. 5.3.2 Injectable

      3. 5.3.3 Nasal

      4. 5.3.4 Other Routes of Administration

   4. 5.4 Geography

      1. 5.4.1 North America

         1. 5.4.1.1 United States

         2. 5.4.1.2 Canada

         3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

         1. 5.4.2.1 Germany

         2. 5.4.2.2 United Kingdom

         3. 5.4.2.3 France

         4. 5.4.2.4 Italy

         5. 5.4.2.5 Spain

         6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

         1. 5.4.3.1 China

         2. 5.4.3.2 Japan

         3. 5.4.3.3 India

         4. 5.4.3.4 Australia

         5. 5.4.3.5 South Korea

         6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East & Africa

         1. 5.4.4.1 GCC

         2. 5.4.4.2 South Africa

         3. 5.4.4.3 Rest of Middle East & Africa

      5. 5.4.5 South America

         1. 5.4.5.1 Brazil

         2. 5.4.5.2 Argentina

         3. 5.4.5.3 Rest of South America

6. 6. COMPETITIVE LANDSCAPE

   1. 6.1 Company Profiles

      1. 6.1.1 Pfizer Inc.

      2. 6.1.2 Novartis International AG

      3. 6.1.3 F. Hoffmann-La Roche AG

      4. 6.1.4 Becton, Dickinson and Company

      5. 6.1.5 Uniqure N.V.

      6. 6.1.6 Shenzhen SiBiono GeneTech Co. Ltd

      7. 6.1.7 Bayer AG

      8. 6.1.8 Amgen Inc.

      9. 6.1.9 Shanghai Sunway Biotech Co. Ltd

   *List Not Exhaustive

7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS